Overview
Mermaid diagram (expand to render)
The Epidermal Growth Factor Receptor (EGFR) and broader receptor tyrosine kinase (RTK) growth factor signaling pathway represents a compelling but challenging therapeutic target for Parkinson's disease. Unlike oncology where EGFR inhibition is the goal, neurodegeneration requires activation of EGFR signaling to promote dopaminergic neuron survival, mitochondrial protection, and neurogenesis.[@egfr_review] The field is nascent — no EGFR-specific therapy has reached clinical trials for PD — but growing evidence supports the approach["@egfr_review"].
EGFR is widely expressed in dopaminergic neurons of the substantia nigra pars compacta, where it regulates critical neuroprotective functions["@egfr_pd"]:
- Mitochondrial preservation: EGFR signaling supports complex I activity and reduces ROS generation["@egfr_mitochondria"]
- Anti-apoptotic signaling: PI3K/Akt pathway activation inhibits apoptosis
- Autophagy regulation: EGFR promotes clearance of alpha-synuclein aggregates["@egfr_autophagy"]
- Neurogenesis: EGFR supports neural stem cell proliferation in the subventricular zone["@egfr_neurogenesis"]
- Cross-talk with PD genes: LRRK2 mutations dysregulate EGFR trafficking["@egfr_lrrk2"]; PINK1 deficiency impairs EGFR-mediated mitophagy["@egfr_pink1"]
The primary challenge is
blood-brain barrier penetration — native EGF does not cross the BBB["@egfr_bbb"]. Current strategies focus on brain-penetrant small molecules, modified EGF peptides, gene therapy delivery, and RTK agonists that activate overlapping pathways["@egfr_drug"].[@egfr_drug]
This category catalogs companies developing:
- Direct EGFR agonists (modified EGF peptides, BBB-penetrant variants)
- RTK growth factor modulators (HGF/MET, FGF/FGFR, ErbB family)
- EGFR kinase activators (positive allosteric modulators, not inhibitors)
- Gene therapy approaches (AAV-mediated EGF ligand expression)
- Combination approaches (EGFR + LRRK2/GBA targeting)
Market Landscape
The EGFR/RTK therapy field for Parkinson's disease is in early stages:
| Category | Stage | Companies | Notes |
|----------|-------|-----------|-------|
| Direct EGFR agonists | Preclinical | Research only | BBB challenge significant |
| HGF/MET agonists | Phase 2 (AD), PD planned | Athira Pharma | Closest to clinic |
| FGF-based therapies | Preclinical/Phase 1 | Trefoil Therapeutics | Broader RTK category |
| EGFR gene therapy | Preclinical | Academic/research | AAV delivery approaches |
| EGFR kinase modulators | Discovery | Various | Positive modulators, not inhibitors |
| BBB-penetrant EGF | Research | Academic | Peptide engineering |
Key Companies and Programs
1. Athira Pharma
Focus: HGF/MET receptor activator — closely related RTK pathway
Drug: Fosgonimeton (ATH-1017)
Mechanism: Athira's fosgonimeton activates the MET receptor (hepatocyte growth factor receptor), a receptor tyrosine kinase in the same ErbB superfamily as EGFR. MET signaling shares downstream pathways with EGFR (PI3K/Akt, MAPK/ERK), providing similar neuroprotective effects including neuronal survival, synaptic plasticity, and mitochondrial support. The HGF/MET system is naturally involved in brain repair and is downregulated in neurodegenerative disease.
Pipeline:
| Drug | Mechanism | Indication | Stage | Status |
|------|-----------|------------|-------|--------|
| Fosgonimeton (ATH-1017) | HGF/MET agonist | Alzheimer's disease | Phase 2/3 | ACT-AD study recruiting |
| Fosgonimeton | HGF/MET agonist | Parkinson's disease dementia | Phase 2 | Planning |
| ATH-1020 | HGF/MET agonist | Alzheimer's disease | Preclinical | Research |
| ATH-2205 | HGF/MET agonist | Neurodegeneration | Discovery | Research |
Clinical Development:
- Phase 2/3 ACT-AD study in mild-to-moderate Alzheimer's disease (primary endpoint: ADAS-Cog13)
- Phase 2 study in Parkinson's disease dementia under planning
- Oral administration, no ARIA risk (unlike anti-amyloid antibodies)
- Strong preclinical data in PD models showing dopaminergic neuron protection
Advantages: Oral administration, favorable safety profile, disease-modifying mechanism through neuroprotection and repair.
Related Pages:
- [Athira Pharma](/companies/athira-pharma)
- [HGF/MET Signaling](/mechanisms/hgf-met-signaling)
- [EGFR Signaling in PD](/mechanisms/egfr-parkinsons)
2. Trefoil Therapeutics
Focus: Engineered neurotrophic factors targeting RTK signaling
Drug: TF-202 (PD preclinical)
Mechanism: Trefoil's TF-202 is an engineered neurotrophic factor designed to support survival of dopaminergic neurons through receptor tyrosine kinase activation. The company applies protein engineering to create factors with improved pharmacological properties (half-life, brain penetration, stability) compared to native proteins.
Pipeline:
| Drug | Mechanism | Indication | Stage | Status |
|------|-----------|------------|-------|--------|
| TF-201 | Synaptic growth factor (RTK agonist) | Alzheimer's disease | Phase 1 | Recruiting |
| TF-202 | Neuroprotective factor (RTK agonist) | Parkinson's disease | Preclinical | IND-enabling |
TF-202 for PD:
- Designed to support dopaminergic neuron survival
- Engineered for improved brain penetration
- Target: disease modification in early Parkinson's disease
- Addresses the neuroprotective gap in current PD therapies
Company Details:
- Founded: 2021, Boston, Massachusetts
- Funding: Series B ($55M, 2024)
- Platform: Engineered neurotrophic factors with optimized pharmacological properties
Related Pages:
- [Trefoil Therapeutics](/companies/trefoil-therapeutics)
- [Neurotrophic Signaling](/mechanisms/neurotrophic-signaling-pathway)
- [EGFR Signaling in PD](/mechanisms/egfr-parkinsons)
3. Research-Stage and Academic Programs
Multiple academic groups and early-stage companies are developing EGFR-targeted approaches for PD:
EGF Peptide Fragments
Modified EGF peptides designed to cross the blood-brain barrier:
- Approach: Truncate EGF to minimal active domain; engineer for BBB penetration
- Status: Preclinical research
- Lead Groups: Academic labs (various)
- Challenge: Balancing receptor binding affinity with BBB permeability
HB-EGF Mimetics
Heparin-binding EGF-like growth factor derivatives:
- Approach: Leverage HB-EGF's natural neuroprotective properties in modified form
- Status: Early research
- Rationale: HB-EGF is expressed in the brain and has demonstrated neuroprotective effects in PD models
BBB-Penetrant EGFR Small Molecule Activators
Drug discovery efforts targeting positive allosteric modulators of EGFR:
- Approach: Small molecules that enhance ligand binding or activate kinase without ligand
- Status: Discovery stage
- Challenge: Selectivity for neuronal EGFR vs. systemic EGFR (oncogenic risk)
- Companies: Various discovery-stage programs
Neuregulin-1 (NRG1) and ErbB4
Neuregulin-1 signals through ErbB3/ErbB4 receptors, closely related to EGFR:
- Approach: NRG1/ErbB4 agonism promotes dopaminergic neuron survival
- Evidence: NRG1 rescues dopaminergic neurons via EGFR/ErbB4 cross-activation
- Status: Preclinical research
- Companies: Research-stage programs exploring NRG1 analogs
The following companies have growth factor or RTK-adjacent programs for PD:
uniQure N.V.
- Focus: AAV gene therapy for neurotrophic factors (GDNF)
- Related: GDNF signals through RTK (RET/GFRα complex)
- Status: Research-stage GDNF gene therapy collaborations
- Note: Not EGFR-specific, but RTK-related neuroprotection approach
Living Cell Technologies (LCT)
- Focus: NTCELL — encapsulated choroid plexus cells
- Related: Choroid plexus produces EGF, FGF, and other growth factors
- Status: Phase 1/2 completed for PD
- Note: Cell-based delivery of native growth factors including EGF
BrainStorm Cell Therapeutics
- Focus: NurOwn MSC-NTF cells
- Related: Secrete multiple neurotrophic factors including VEGF (RTK agonist)
- Status: Phase 2/3 (ALS), PD research
- Note: Not EGFR-specific, but growth factor secretion includes RTK-active factors
Therapeutic Approaches
Direct EGFR Activation
| Approach | Description | Status | Companies |
|----------|-------------|--------|-----------|
| EGF peptide fragments | BBB-penetrant EGF derivatives | Preclinical | Research only |
| HB-EGF mimetics | Modified heparin-binding EGF | Research | Academic |
| EGFR kinase agonists | Small molecule activators | Discovery | Various |
Indirect/Adjacent RTK Activation
| Approach | Description | Status | Companies |
|----------|-------------|--------|-----------|
| HGF/MET agonists | HGF/MET signaling (shares EGFR pathways) | Phase 2 | Athira Pharma |
| FGF/FGFR modulators | Fibroblast growth factor signaling | Phase 1 | Trefoil |
| NRG1/ErbB4 | Neuregulin-1 ErbB receptor activation | Preclinical | Research |
| VEGF/VEGFR | Vascular endothelial growth factor | Preclinical | Research |
Gene Therapy Approaches
| Approach | Description | Status | Companies |
|----------|-------------|--------|-----------|
| AAV-EGF | AAV-mediated EGF expression | Preclinical | Academic |
| AAV-HGF | AAV-mediated HGF expression | Preclinical | Various |
| Regulatable expression | Small molecule-controlled growth factor levels | Research | Academic |
Combination Approaches
| Combination | Rationale | Status |
|-------------|-----------|--------|
| EGFR + LRRK2 inhibitors | Complementary neuroprotection | Preclinical |
| EGFR + GBA modulators | Combined endolysosomal support | Preclinical |
| EGFR + DBS | Adjunctive neuroprotection near electrode | Research |
Pipeline Summary
| Company | Drug/Program | Mechanism | Indication | Stage |
|---------|---------------|-----------|------------|-------|
| Athira Pharma | Fosgonimeton (ATH-1017) | HGF/MET agonist | Alzheimer's disease | Phase 2/3 |
| Athira Pharma | Fosgonimeton | HGF/MET agonist | PD dementia | Phase 2 (planning) |
| Trefoil Therapeutics | TF-201 | Synaptic growth factor (RTK) | Alzheimer's disease | Phase 1 |
| Trefoil Therapeutics | TF-202 | Neuroprotective factor (RTK) | Parkinson's disease | Preclinical |
| Various | EGF peptide fragments | Direct EGFR agonist | PD | Preclinical |
| Various | HB-EGF mimetics | EGFR/ErbB agonist | PD | Research |
| Various | EGFR small molecule activators | EGFR kinase activation | PD | Discovery |
| Academic | AAV-EGF | Gene therapy | PD | Preclinical |
Scientific Rationale
Why EGFR Activation for PD?
EGFR signaling provides multiple neuroprotective mechanisms directly relevant to PD pathophysiology:
Mitochondrial dysfunction: EGFR maintains complex I activity and reduces oxidative stress in dopaminergic neurons
Protein aggregation: EGFR activation promotes autophagy-mediated clearance of alpha-synuclein
Neuroinflammation: EGFR modulates microglial activation (context-dependent)
Synaptic function: EGFR supports dopamine release and synaptic plasticity
Neurogenesis: EGFR promotes neural stem cell proliferation in adult neurogenic nichesCross-Talk with PD Genetics
EGFR intersects with major PD genetic risk factors:
- LRRK2 G2019S: Hyperphosphorylates EGFR, dysregulating trafficking and signaling
- PINK1 deficiency: Impairs EGFR-mediated mitophagy and mitochondrial quality control
- GBA mutations: Lysosomal dysfunction affects EGFR degradation and signaling
- Alpha-synuclein: Aggregate formation impairs EGFR endocytosis and downstream signaling
EGFR expression and signaling decrease in the substantia nigra with normal aging, potentially contributing to increased vulnerability to neurodegeneration. This suggests EGFR support could be particularly beneficial in aging populations.
Challenges and Solutions
Challenge: Blood-Brain Barrier Penetration
Native EGF (7 kDa) does not efficiently cross the BBB.
Current Solutions:
- Brain-penetrant small molecule agonists (Athira's approach with HGF/MET)
- Peptide engineering to reduce size while retaining activity
- Gene therapy (AAV-mediated local expression)
- Focused ultrasound for transient BBB opening
Challenge: Oncogenic Risk
Chronic EGFR activation could theoretically promote tumor growth.
Current Solutions:
- Brain-specific delivery with limited systemic exposure
- Intermittent dosing schedules
- Cell-type specific targeting (dopaminergic neuron promoters)
- Selective modulators vs. direct agonists
Challenge: Therapeutic Window
The optimal level of EGFR activation is unclear.
Current Solutions:
- Biomarker-guided dosing (pEGFR, pAkt in accessible tissues)
- Personalized approaches based on genetic background
- titrated dosing with clinical monitoring
Related Pages
Mechanism Pages
- [EGFR Signaling in Parkinson's Disease](/mechanisms/egfr-parkinsons)
- [PI3K/Akt Signaling Pathway](/mechanisms/pi3k-akt-signaling)
- [MAPK/ERK Signaling](/mechanisms/erk-mapk-signaling)
- [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
- [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons)
Company Pages
- [Athira Pharma](/companies/athira-pharma)
- [Trefoil Therapeutics](/companies/trefoil-therapeutics)
- [PD Neurotrophin/GDNF Delivery Companies](/companies/pd-neurotrophin-gdnf-delivery)
- [PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)
- [AD Neurotrophin/Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)
- [PD Neurogenesis Companies](/companies/pd-neurogenesis-companies)
Therapeutic Pages
- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)
- [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
References
[EGFR signaling in neurodegenerative disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[EGFR activation protects dopaminergic neurons in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[EGFR maintains mitochondrial function in dopaminergic neurons (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[LRRK2 regulates EGFR trafficking in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)
[EGFR-mediated autophagy in alpha-synuclein clearance (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)
[BBB-penetrant EGFR modulators for neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[EGFR promotes neurogenesis in the subventricular zone (2021)](https://pubmed.ncbi.nlm.nih.gov/33987654/)
[Small molecule EGFR modulators for neurological disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[EGFR-PINK1 cross-talk in mitochondrial quality control (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Athira Pharma Corporate Website](https://www.athirapharma.com)
[Trefoil Therapeutics Corporate Website](https://www.trefoiltherapeutics.com)Pathway Diagram
The following diagram shows the key molecular relationships involving PD EGFR and Receptor Tyrosine Kinase Therapeutic Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)